Neurological Surgery 脳神経外科50巻1号

2022年01月発行

特集 Precision Medicine—個別化医療を目指した遺伝子診断と新治療の知見 Ⅰ悪性脳腫瘍

髄芽腫

著者： 金村米博¹²

所属機関： ¹国立病院機構大阪医療センター臨床研究センター先進医療研究開発部 ²国立病院機構大阪医療センター脳神経外科

ページ範囲：P.73 - P.90

Point
・髄芽腫は分子遺伝学的特性に基づき，予後を含めた臨床的特徴が異なる複数の分子亜群，亜型に分類される．
・従来の臨床的リスク分類に加えて，分子診断に基づくリスク評価が実施されるようになり，治療戦略決定の際に分子診断情報は必須である．
・治療成績の向上と治療関連副作用軽減のためには，分子診断に応じた分子標的薬の使用など個別化医療の実践が重要である．

参考文献

1）Taylor MD, et al：Molecular subgroups of medulloblastoma：the current consensus. Acta Neuropathol 123：465-472, 2012

2）Ellison DW, et al：Medulloblastoma. WHO Classification of Tumours of the Central Nervous System, revised 4th Edition. IARC, Lyon, 2016, pp. 184-200

3）Louis DN, et al：The 2021 WHO Classification of Tumors of the Central Nervous System：a summary. Neuro Oncol 23：1231-1251, 2021

4）Cavalli FMG, et al：Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell 31：737-754, 2017

5）Schwalbe EC, et al：Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma：a cohort study. Lancet Oncol 18：958-971, 2017

6）Northcott PA, et al：The whole-genome landscape of medulloblastoma subtypes. Nature 547：311-317, 2017

7）Hovestadt V, et al：Medulloblastomics revisited：biological and clinical insights from thousands of patients. Nat Rev Cancer 20：42-56, 2020

8）Kumar R, et al：Medulloblastoma genomics in the modern molecular era. Brain Pathol 30：679-690, 2020

9）Lospinoso Severini L, et al：The SHH/GLI signaling pathway：a therapeutic target for medulloblastoma. Expert Opin Ther Targets 24：1159-1181, 2020

10）Garcia-Lopez J, et al：Deconstructing sonic hedgehog medulloblastoma：molecular subtypes, drivers, and beyond. Trends Genet 37：235-250, 2021

11）Robinson GW, et al：Risk-adapted therapy for young children with medulloblastoma（SJYC07）：therapeutic and molecular outcomes from a multicentre, phase 2 trial. Lancet Oncol 19：768-784, 2018

12）Kool M, et al；ICGC PedBrain Tumor Project：Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell 25：393-405, 2014

13）Waszak SM, et al：Germline elongator mutations in sonic hedgehog medulloblastoma. Nature 580：396-401, 2020

14）Sharma T, et al：Second-generation molecular subgrouping of medulloblastoma：an international meta-analysis of Group 3 and Group 4 subtypes. Acta Neuropathol 138：309-326, 2019

15）Zeltzer PM, et al：Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children：conclusions from the Children's Cancer Group 921 randomized phase Ⅲ study. J Clin Oncol 17：832-845, 1999

16）Packer RJ, et al：Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy：a Children's Cancer Group Study. J Clin Oncol 17：2127-2136, 1999

17）Packer RJ, et al：Phase Ⅲ study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24：4202-4208, 2006

18）Gajjar A, et al：Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy：results of an international phase Ⅲ trial（SJMB03）. J Clin Oncol 39：822-835, 2021

19）Goschzik T, et al：Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma：a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial. Lancet Oncol 19：1602-1616, 2018

20）Leary SES, et al：Efficacy of carboplatin and isotretinoin in children with high-risk medulloblastoma：a randomized clinical trial from the Children's Oncology Group. JAMA Oncol 7：1313-1321, 2021

21）Rutkowski S, et al：Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 352：978-986, 2005

22）Mynarek M, et al：Nonmetastatic medulloblastoma of early childhood：results from the prospective clinical trial HIT-2000 and an extended validation cohort. J Clin Oncol 38：2028-2040, 2020

23）Lafay-Cousin L, et al：Clinical, pathological, and molecular characterization of infant medulloblastomas treated with sequential high-dose chemotherapy. Pediatr Blood Cancer 63：1527-1534, 2016

24）Ramaswamy V, et al：Risk stratification of childhood medulloblastoma in the molecular era：the current consensus. Acta Neuropathol 131：821-831, 2016

25）Wen J, Hadden MK：Medulloblastoma drugs in development：current leads, trials and drawbacks. Eur J Med Chem 215：113268, 2021

26）Rudin CM, et al：Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 361：1173-1178, 2009

27）Robinson GW, et al：Vismodegib exerts targeted efficacy against recurrent sonic hedgehog-subgroup medulloblastoma：results from phase Ⅱ Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. J Clin Oncol 33：2646-2654, 2015

28）Frappaz D, et al：MEVITEM-a phase Ⅰ/Ⅱ of vismodegib ＋ temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with sonic hedgehog pathway activation. Neuro Oncol 23：1949-1960, 2021

29）Li Y, et al：Phase Ⅰ and phase Ⅱ sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients：a systemic review and meta-analysis. Acta Neuropathol Commun 7：123, 2019

30）Robinson GW, et al：Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor. Oncotarget 8：69295-69302, 2017

31）Michalski JM, et al：Children's Oncology Group phase Ⅲ trial of reduced-dose and reduced-volume radiotherapy with chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 39：2685-2697, 2021